Significant Options Trading on Wednesday: AMGN, SD, JNJ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy AMGN?
Source: NASDAQ.COM
SandRidge Energy Options Activity: SandRidge Energy Inc (SD) has seen a trading volume of 1,383 options contracts today, equating to about 138,300 underlying shares, which is 51.6% of its average daily trading volume over the past month.
High Volume Call Option for SandRidge: The $15 strike call option expiring on April 17, 2026, has particularly high activity with 764 contracts traded, representing approximately 76,400 underlying shares.
Johnson & Johnson Options Activity: Johnson & Johnson (JNJ) reported an options trading volume of 38,997 contracts today, which corresponds to around 3.9 million underlying shares, or 51% of its average daily trading volume over the past month.
High Volume Call Option for Johnson & Johnson: The $175 strike call option expiring on November 21, 2025, has seen significant trading with 3,133 contracts, representing about 313,300 underlying shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 373.360
Low
280.00
Averages
363.10
High
425.00
Current: 373.360
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMGEN INC SUBMITS SEC FILING FOR FOUR PART NOTES OFFERING; SIZE UNDISCLOSED
Filing for Partnership Notes: AMGEN has filed for four partnership notes offering.
Size Disclosure: The size of the offering has not been disclosed.
See More
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
UPLIZNA Approved for Adult gMG Treatment in Europe
- New Therapy Approval: UPLIZNA (Inebilizumab) has been approved by the European Commission as an adjunct treatment for adults with anti-AChR+ and anti-MuSK+ generalized Myasthenia Gravis (gMG), marking a significant advancement in this field.
- Long-term Disease Control: The therapy demonstrates potential for sustained disease control in gMG patients through a biannual maintenance dose following two initial infusions, which may reduce the need for long-term steroid use.
- Clinical Research Support: The approval is based on data from the MINT study, the largest Phase 3 trial for gMG, involving 238 patients, where 87.4% of UPLIZNA patients successfully reduced their steroid dosage to 5mg or less per day by week 26.
- Market Impact: The approval of UPLIZNA provides a new treatment option for gMG patients, expected to enhance patient quality of life while bolstering Amgen's market position in the rare disease sector.
See More
Amgen to Present at 2026 Oncology Leadership Summit
- Event Schedule: Amgen will participate in Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, at 12:15 p.m. PT, where Jean-Charles Soria, Senior Vice President of Oncology, will present the company's latest advancements in oncology.
- Webcast Availability: The presentation will be broadcast live over the internet, accessible to media, investors, and the public, ensuring broad dissemination of information, and will be archived on Amgen's website for at least 90 days for later viewing.
- Company Background: Founded over 45 years ago, Amgen is dedicated to discovering, developing, and manufacturing innovative medicines targeting cancer, heart disease, inflammatory conditions, rare diseases, and obesity, continuously pushing the boundaries of the biotechnology industry and showcasing strong market competitiveness.
- Industry Recognition: Amgen has been recognized for its innovation and workplace culture by Fast Company and Forbes, and is a constituent of the Dow Jones Industrial Average and Nasdaq-100 Index, highlighting its leadership and influence in the biopharmaceutical sector.
See More
AMGEN INC: SUBMITS SEC FILING FOR COMMON STOCK OFFERING BY SELLING SECURITYHOLDERS
- Company Filing: AMGEN has filed for offering common stock by selling security holders.
- Purpose of Offering: The offering is intended to provide liquidity for the selling security holders.
See More
AMGEN INC: SUBMITS MIXED SHELF OFFERING; SIZE UNREVEALED - SEC FILING
Company Filing: AMGEN has filed for a mixed shelf offering, allowing it to raise capital through various securities.
Size Disclosure: The specific size of the offering has not been disclosed in the filing.
See More
AMGEN INC SUBMITS SEC FILING FOR FOUR PART NOTES OFFERING; SIZE UNDISCLOSED
Filing for Partnership Notes: AMGEN has filed for four partnership notes offering.
Size Disclosure: The size of the offering has not been disclosed.
See More
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
UPLIZNA Approved for Adult gMG Treatment in Europe
- New Therapy Approval: UPLIZNA (Inebilizumab) has been approved by the European Commission as an adjunct treatment for adults with anti-AChR+ and anti-MuSK+ generalized Myasthenia Gravis (gMG), marking a significant advancement in this field.
- Long-term Disease Control: The therapy demonstrates potential for sustained disease control in gMG patients through a biannual maintenance dose following two initial infusions, which may reduce the need for long-term steroid use.
- Clinical Research Support: The approval is based on data from the MINT study, the largest Phase 3 trial for gMG, involving 238 patients, where 87.4% of UPLIZNA patients successfully reduced their steroid dosage to 5mg or less per day by week 26.
- Market Impact: The approval of UPLIZNA provides a new treatment option for gMG patients, expected to enhance patient quality of life while bolstering Amgen's market position in the rare disease sector.
See More
Amgen to Present at 2026 Oncology Leadership Summit
- Event Schedule: Amgen will participate in Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, at 12:15 p.m. PT, where Jean-Charles Soria, Senior Vice President of Oncology, will present the company's latest advancements in oncology.
- Webcast Availability: The presentation will be broadcast live over the internet, accessible to media, investors, and the public, ensuring broad dissemination of information, and will be archived on Amgen's website for at least 90 days for later viewing.
- Company Background: Founded over 45 years ago, Amgen is dedicated to discovering, developing, and manufacturing innovative medicines targeting cancer, heart disease, inflammatory conditions, rare diseases, and obesity, continuously pushing the boundaries of the biotechnology industry and showcasing strong market competitiveness.
- Industry Recognition: Amgen has been recognized for its innovation and workplace culture by Fast Company and Forbes, and is a constituent of the Dow Jones Industrial Average and Nasdaq-100 Index, highlighting its leadership and influence in the biopharmaceutical sector.
See More
AMGEN INC: SUBMITS SEC FILING FOR COMMON STOCK OFFERING BY SELLING SECURITYHOLDERS
- Company Filing: AMGEN has filed for offering common stock by selling security holders.
- Purpose of Offering: The offering is intended to provide liquidity for the selling security holders.
See More
AMGEN INC: SUBMITS MIXED SHELF OFFERING; SIZE UNREVEALED - SEC FILING
Company Filing: AMGEN has filed for a mixed shelf offering, allowing it to raise capital through various securities.
Size Disclosure: The specific size of the offering has not been disclosed in the filing.
See More
